Imatinib mesylate
Idiopathic Pulmonary Fibrosis
Clinical trials
3
Developer
Stanford University
Overview
Imatinib mesylate is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 3 tracked IPF clinical trials.
Imatinib mesylate clinical trials
Explore related
Medical disclaimer. This page summarizes research about Imatinib mesylate for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.